Hemophagocytic lymphohistiocytosis (HLH) is characterized by hyperinflammation and life-threatening cytopenias. Survival is poor, and management is pivotal on rapid identification of the disease. HLH is associated with hematologic malignancies, however correlation with myelodysplastic syndromes (MDS) is exceedingly unusual. Although minimizing overwhelming hyperinflammation by treating hemophagocytosis are central for HLH outcome, there is urgent necessity to identify potential initiating mechanisms that could assist in therapy design.
Case description
Here, we describe an elderly African American patient who developed rapid onset of cytopenias and coagulopathy associated with hepatic and bone marrow hemophagocytosis. We analyze four additional similar cases to isolate clinical, laboratory and cytogenetic findings expected in patients exhibiting concurrent HLH and MDS. HLH linked with MDS retains common HLH features associated with systemic hyperinflammation such as fever, hypotension, hepatosplenomegaly, hyperferritinemia, coagulopathy and rapidly evolving cytopenias. Typical MDS chromosomic abnormality such as trisomy 8 was frequently observed in our studied cases.
Conclusion
Our case describes difficulties while managing HLH in MDS patients. Diagnosis should be based on identifying HLH appropriate criteria and if possible karyotypic abnormalities normally observed in MDS.
Hinweise
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Abkürzungen
HLH
Hemophagocytic lymphohistiocytosis
MDS
Myelodysplastic syndrome
HMA
Hypomethylating agent
Introduction
Hemophagocytic lymphohistiocytosis (HLH) is characterized by deregulated immunity and end organ damage. Primary HLH is linked with autosomal recessive and X-linked mutations. Secondary HLH results from predisposing conditions. Both primary and secondary HLH may be activated by an infections and malignancies. [1] The association of HLH with hematologic malignancies is accepted. However, HLH initiated by myelodysplastic syndrome (MDS) is exceedingly unusual. Although dysplasia is observed in patients with hemophagocytosis, a hyperinflammatory entity characterized by dysplastic cytopenias, MDS like karyotypic abnormality and hemophagocytosis suggests a different spectrum of disease, in which HLH originates from a clonal disorder. In this report, we present an elderly female who fulfilled HLH 2004 criteria exhibiting erythroid and megakaryocytic dysplasia associated with trisomy 8 [+ 8]. Additionally, we examine published cases in English literature to identify clinical, laboratory and cytogenetic features observed in MDS patients fulfilling HLH 2004 criteria.
Case presentation
An 83-year-old African American female presented with lethargy, temperature of 102.9° F and tachycardia. After 9 days of broad-spectrum antibiotics, she developed hemodynamic instability requiring vasopressors, worsening liver function (peak bilirubin of 12.5 mg/dL, Aspartate aminotransferase (AST) of 689 IU/L, Alanine aminotransferase (ALT) of 239 IU/L) and leukocytosis of 16,000/uL. Her hemoglobin was 8.9/uL and platelets had fallen to 26,000/uL. Disseminated intravascular coagulation (DIC) was considered given progressive severe thrombocytopenia of 13,000 U/L, fibrinogen < 70 mg/dL and d-dimer of 12.4 mg/L. Her ferritin was 9479 ng/mL and fasting triglycerides (TAG) were 321 mg/dL. Soluble interleukin-2Rα (CD25) was < 38 pg/dL. Her human immunodeficiency virus (HIV), rapid influenza A/B, hepatitis B/C serologies were all negative. Epstein-barr virus (EBV) viral load was negative. Given concern autoimmune hepatitis, a liver biopsy showed Kupffer cell hypertrophy with hemophagocytosis. Bone marrow biopsy demonstrated hemophagocytosis (Fig 1a, b). In addition, significant erythroid nuclear fragmentation and karyorrhexis were observed (Fig 1c). Marrow cytogenetics showed 47, XX +8 [6], 46, XX [5]. Next generation sequencing (NGS) including CSFR1, SF3B1, SRSF2, U2AF1, NRAS, KRAS, FLT3, JAK2, KIT, PHF6, PDGFRA, CDKN2A, IDH1, IDH2, TET2, EZH2, CEBPA, EP300, PTPN11, P53, CREBBP, IKZF1, IKZF3, NOTCH1, RUNX1, WT1 and NPM1 showed DNMT3A p.Arg736His (c.2207G>A) and DNMT3A p.Leu859Ter (c.2576T>A) at allele frequencies of 2.7 and 2.4 %, respectively. In view of her hemophagocytosis, cytopenias, high temperature, abnormal liver function test, low fibrinogen and elevated fasting triglycerides and ferritin, she fulfilled 5/8 HLH 2004 criteria. HLH-94 regimen was initiated with dexamethasone and etoposide. She developed neutropenic sepsis and etoposide was stopped. Blood cultures were positive for Escherichia coli. Patient expired after developing hemodynamic instability.
×
Anzeige
Methods
In addition to our case, three additional previously published reports were included in our reviewed cases. Clinical, laboratory and karyotypic data was analyzed to investigate potential features commonly observed in patients presenting with hyperinflammation and MDS. Data aggregation from four cases presenting with HLH and MDS allowed identification of clinical outcome in patients receiving HLH directed therapy or alternative regimens.
Cohort analysis
HLH is a deadly syndrome. If untreated, survival is less than 2 months [2]. Here, we describe an elderly female exhibiting hyperinflammation, refractory cytopenias, erythroid dysplasia, expansion of + 8 metaphases and bone marrow/hepatic hemophagocytosis suggesting HLH associated with MDS (HLH-MDS). In addition to our patient, three previously published HLH cases associated with MDS were included in study cohort (Table 1). 7/8 HLH criteria were observed in two (50%), and one (25%) case with 6/8 and 5/8 criteria, each. Our report and published cases are novel since 3 of 4 (75%) patients harbored a karyotypic abnormality highlighting the clonal nature of the disease. A detectable chromosomic abnormality suggests that HLH was systemically initiated by MDS rather than representing a reactive phenomenon [3-5]. In reviewed cases, patients were older than 60 years with exception of one pediatric patient. International prognostic score system (IPSS) was intermediate-1 and high-risk (2 cases, each). + 8 was detected as sole abnormality or within a complex metaphase in 75% of cases. Most of the patients succumbed to the disease, except one case treated with high dose methylprednisolone, cyclosporine (CSA) decitabine. Tamamyan et al. described 33 cases of HLH, of which 3(9%) exhibited concurrent MDS, although only one was identified by HLH 2004 [6]. Karyotypic abnormalities were not reported. As in our case, the author reported that HLH linked with MDS represented a fatal condition.
Table 1
Myelodysplastic syndrome cases associated with hemophagocytic Lymphohistiocytosis (HLH)
Age (years)
Fever
ANC (/mL)
Hb (g/dL)
Platelet (K/UL)
Ferritin (ng/dL)
Fibrinogen (mg/dL)
TAG (mg/dL)
IL-2 (pg/dL)
Hemophagocytosis
Marrow blast (%)
Karyotype
R-IPSS
Hepatomegaly/splenomegaly
HLH-2004 (points)
Outcome
1
8
Yes
400
10.6
49
1070
256
306
4250
Yes
2.2
46, XX, + 8 [20]
Inter-mediate
Yes/yes
5
Alive
2
60
Yes
6800
6.5
14
649
NA
NA
4054
Yes
2
Complex [including + 8]a
Very high
Yes/yes
5
Alive
3
68
NA
NA
10.5
45
24,316
129
NA
1025
Yes
0
46, XY
Low
No/yes
5
Died
Case
83
Yes
8900
8.9
13
9479
70
321
34
Yes
0
47, XX, + 8 [6], 46, XX [5]
Low
No/no
6
Died
ANC absolute neutrophil count, Hb hemoglobin, TAG triglycerides, IL2 Interleukin 2 soluble receptor, IPSS International Prognostic Score System, NA not available
Efforts to elucidate pathogenesis of HLH demonstrate that expansion of CD8+ cytotoxic T cells, low Treg frequencies and cytokine storm are frequently observed [7]. In MDS, similar clonal T cell expansion and decreased Treg frequencies results in stem cell/progenitor apoptosis in low-risk disease. Rather than hyperinflammation normally found in HLH patients, chronic low-grade inflammation develops associated with tumor-necrosis factor-alpha (TNF-α), interleukin 1-beta (IL-1β) and IL-6 upregulation. Cytokine abnormalities in MDS leads to increased apoptosis and marrow hypercellularity. However, decreased marrow cellularity can develop in fraction of MDS patients harboring trisomy 8 karyotypic abnormality. Interestingly, our patient and two previously published cases harbored + 8 in their metaphase analysis at MDS diagnosis while HLH had developed [3, 5]. + 8 cells induce autologous T-cell oligoclonal expansion capable to target MDS precursor/progenitors resulting in characteristic marrow hypoplasia [8, 9]. In most of MDS cases, disease propagation depends on somatic mutations acquisition allowing dysplastic transformation. Mutations in perforin-dependent cytotoxicity are classically described in primary HLH. In our case, it is conceivable that myeloid mutations induced apoptotic and differentiation defects, and “facilitated” acquisition of HLH-like phenotype.
The preferred HLH treatment is HLH-94 protocol, but its administration is limited by MDS-induced cytopenias, as was the case with our patient. This is largely due to hemopoietic progenitor depletion initiated MDS and likely aggravated by HLH. Daitoku et al. reports superior outcome in a HLH-MDS patient treated with Methylprednisolone, CSA and decitabine[4]. Indeed, in vivo administration of hypomethylating agents (HMA) induce Foxp3+ Tregs expansion leading to immune suppression, and attenuates graft-versus-host disease [10]. The combination of HMA and immunosuppressive therapy may be promising treatment in HLH-MDS cases as suggested by the interesting outcomes in the case described by Daitoku et al.
Anzeige
We acknowledge limitations to our interpretation. It is possible that hyperinflammation initiated by HLH led to marrow dysplasia. However, the evidence of +8 strongly suggests a clonal etiology supporting MDS induced HLH. Secondly, sequencing did not include HLH like mutations such as PRF1, STX11, UNC13D, STXBP2, RAB27A, SH2D1A, BIRC4, LYST, ITK, SLC7A7, XMEN, HPS, among others. This may affect our ability to assign HLH as culprit for hyperinflammation in our case. However, Rui et al. recently demonstrated that epigenetic perturbations induced by DNMT3A mutations results in aberrant stem cell gene-expression associated with immune deregulation, which may have contributed to inflammatory manifestations in our case [11]. Additionally, recent data demonstrated that myeloid specific mutations including TET2, ASXL1, and DNMT3A can induce inflammasome activation in myelodysplasia and exacerbate inflammation [12-15]. In summary, HLH associated with MDS is an aggressive entity and should prompt careful evaluation hyperinflammatory signs. It is possible that targeting MDS hematopoiesis with hypomethylating agents in combination with immunosuppressive therapy to minimize hyperinflammation could improve life-threatening HLH in MDS patients.
Acknowledgements
Financial support for this study was provided by the Texas Golfers against Cancer grant funding.
Ethic approval and consent to participate
Institutional Review Board (IRB) approval was obtained for publication.
Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
Competing interest
Dr. Sun, Dr. Blieden, Dr. Merritt, Dr. Sosa and Dr. Rivero reported no conflict of interest.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Mit e.Med Allgemeinmedizin erhalten Sie Zugang zu allen CME-Fortbildungen und Premium-Inhalten der allgemeinmedizinischen Zeitschriften, inklusive einer gedruckten Allgemeinmedizin-Zeitschrift Ihrer Wahl.